The Monash IVF Group's result was pre-released and Morgans says the the highlights were a strong balance sheet and market share growth in NSW, QLD and SA, which were offset by a weaker result in Vic and Malaysia.

The broker points out pent-up demand from the suspension of services in April and May is likely to result in record cycle numbers in July, August and September.

No final dividend was declared, although the deferred interim dividend of 2.1cps will be paid on October 2.

The Add rating is maintained. The target price is increased to $0.65 from $0.63.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $0.65.Current Price is $0.58. Difference: $0.07 - (brackets indicate current price is over target). If MVF meets the Morgans target it will return approximately 11% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena